Commentary on: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy

Urology. 2017 Jul:105:13. doi: 10.1016/j.urology.2017.01.006. Epub 2017 Jan 12.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents
  • Carcinoma, Renal Cell*
  • Humans
  • Indoles
  • Kidney Neoplasms
  • Nephrectomy*
  • Pyrroles
  • Sunitinib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib